类有机物
毒性
三维细胞培养
肝毒性
药物毒性
药品
体外
计算生物学
生物
药理学
医学
细胞生物学
内科学
生物化学
作者
Anastasia Brooks,Xiaowen Liang,Yonglong Zhang,Chun‐Xia Zhao,Michael S. Roberts,Haolu Wang,Lei Zhang,Dorothy H. Crawford
标识
DOI:10.1016/j.phrs.2021.105608
摘要
The past decade has seen many advancements in the development of three-dimensional (3D) in vitro models in pharmaceutical sciences and industry. Specifically, organoids present a self-organising, self-renewing and more physiologically relevant model than conventional two-dimensional (2D) cell cultures. Liver organoids have been developed from a variety of cell sources, including stem cells, cell lines and primary cells. They have potential for modelling patient-specific disease and establishing personalised therapeutic approaches. Additionally, liver organoids have been used to test drug efficacy and toxicity. Herein we summarise cell sources for generating liver organoids, the advantages and limitations of each cell type, as well as the application of the organoids in modelling liver diseases. We focus on the use of liver organoids as tools for drug validation and toxicity assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI